TGen-US Oncology data guides treatment of metastatic triple-negative breast cancer patients

Unprecedented genomic sequencing of 14 metastatic TNBC patients yields potential drug targets

2012-12-07

(Press-News.org) PHOENIX, Ariz. — Dec. 6, 2012 — Genomic sequencing has revealed therapeutic drug targets for difficult-to-treat, metastatic triple-negative breast cancer (TNBC), according to an unprecedented study by the Translational Genomic Research Institute (TGen) and US Oncology Research.

The study is published by the journal Molecular Cancer Therapeutics and is currently available online.

By sequencing, or spelling out, the billions of letters contained in the genomes of 14 tumors from ethnically diverse metastatic TNBC patients, TGen and US Oncology Research investigators found recurring significant mutations and other changes in more than a dozen genes. In addition, the investigators identified mutations previously unseen in metastatic TNBC and took the sequencing data into account in selection of therapeutic protocols specific to each patient's genetic profile.

"This study stands as a one-of-a-kind effort that has already led to potentially beneficial clinical trials, and sets the stage for future investigations," said Dr. John Carpten, Ph.D., TGen's Deputy Director of Basic Science and Director of TGen's Integrated Cancer Genomics Division, and the study's senior author.

The most frequently mutated gene among the tumors (seven of 14) was the TP53 tumor suppressor, and aberrations were observed in additional tumor suppressor genes including CTNNA1, which was detected in two of six African American patients (who typically have more aggressive and treatment-resistant disease). Alterations were also seen in the ERBB4 gene, known to be involved in mammary-gland maturation during pregnancy and lactation, but not previously linked to metastatic TNBC.

The study included an "outlier analysis," which assessed expression patterns for each tumor when compared against the other tumors examined in the study. Specific cancer genes overexpressed among tumors in the study's cohort included: ALK, AR, ARAF, BRAF, FGFR2, GLI1, GLI2, HRAS, HSP90AA1, KRAS, MET, NOTCH2, NOTCH3, and SHH. Significantly underexpressed cancer genes included: BRCA1, BRCA2, CDKN2A, CTNNA1, DKK1, FBXW7, NF1, PTEN, and SFN.

Each tumor was genomically unique, but nine of the 14 contained alterations in one or both of two particular cellular pathways: RAS/RAF/MEK/ERK and PI3K/AKT/MTOR. Targeted therapeutic intervention aimed at these pathways achieved impressive responses in several cases.

"Importantly, the analysis provided insights into the potential unique therapeutic vulnerabilities of each cancer," said Dr. Joyce O'Shaughnessy, M.D., the study's other co-lead author. Dr. O'Shaughnessy is a practicing oncologist with Texas Oncology — an affiliate of The US Oncology Network — and is the Celebrating Women Chair of Breast Cancer Research at Baylor Charles A. Sammons Cancer Center.

Metastatic TNBC is a highly aggressive form of breast cancer that disproportionately affects African-Americans. It is called triple-negative because tumors do not express the estrogen receptor, progesterone receptor or HER-2, the biomarkers successfully targeted in most breast cancers.

Metastatic TNBC also has a poor prognosis once the cancer has spread to other organs, with a median survival rate among metastatic patients of only one year. While TNBC accounts for only about 15 percent of all breast cancers, its more aggressive biology makes it responsible for nearly one in four deaths related to this disease.

"The nature of this disease cries out for innovative research techniques such as whole genome sequencing coupled with new tools for data analysis," said Dr. David Craig, Ph.D., TGen's Deputy Director of Bioinformatics, and one of the study's co-lead authors.

"We are aware that these results are preliminary and based on a small series of patients," said Carpten. "However, our study will pave the way for new clinical trials and novel hypotheses for future testing in a very difficult to treat cancer."

Whole-genome sequencing of tumors and normal tissue was performed on Life Technologies Corporation's Applied Biosystems SOLiD™ 4.0 platform, and results were validated in a CLIA-certified laboratory.

### The study, "Genome and transcriptome sequencing in prospective triple negative breast cancer uncovers therapeutic vulnerabilities," is sponsored by the Translational Genomics Research Institute (TGen) and US Oncology Research with support from Life Technologies Corporation.

Molecular Cancer Therapeutics is one of several peer-reviewed scientific journals published by the 34,000-member American Association for Cancer Research (AACR), the oldest and largest scientific organization in the world focused on every aspect of high-quality, innovative cancer research. The programs and services of the AACR foster the exchange of knowledge and new ideas among scientists dedicated to cancer research, provide training opportunities for the next generation of cancer researchers, and increase public understanding of cancer.

About TGen The Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life changing results. Research at TGen is focused on helping patients with diseases such as cancer, neurological disorders and diabetes. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process. For more information, visit: www.tgen.org.

About US Oncology Research Supported by McKesson Specialty Health and The US Oncology Network, US Oncology Research draws from a network of experienced investigators and dedicated clinical staff who specialize in Phase I through Phase IV oncology clinical trials. US Oncology Research serves more than 85 practices in nearly 250 locations managing more than 225 active trials at any given time. Physicians in the research network have enrolled more than 53,000 patients in over 1,200 trials since inception in 1992 and have contributed to the development of 43 cancer therapies approved by the FDA. For more information call (800) 482-6700, option 4 or visit www.usoncology.com/oncologists.

Contacts:

Translational Genomics Research Institute
Steve Yozwiak
Senior Science Writer
602-343-8704
syozwiak@tgen.org US Oncology Research and Texas Oncology
Claire Crye
281-863-6783
281-825-9927
claire.crye@mckesson.com END

ELSE PRESS RELEASES FROM THIS DATE:

General thoracic surgeons emerge as leading providers of complex, noncardiac thoracic surgery

2012-12-07

While thoracic surgeons are traditionally known as the experts who perform heart surgeries, a UC Davis study has found that general thoracic surgeons, especially those at academic health centers, perform the vast majority of complex noncardiac operations, including surgeries of the esophagus and lungs. The authors said their results, published in the October issue of The Annals of Thoracic Surgery, support the designation of general thoracic surgery as a distinct specialty, which will benefit patients when selecting surgeons for specific procedures. "In years past, ...

Apollo's lunar dust data being restored

2012-12-07

Forty years after the last Apollo spacecraft launched, the science from those missions continues to shape our view of the moon. In one of the latest developments, readings from the Apollo 14 and 15 dust detectors have been restored by scientists with the National Space Science Data Center (NSSDC) at NASA's Goddard Space Flight Center in Greenbelt, Md. "This is the first look at the fully calibrated, digital dust data from the Apollo 14 and 15 missions," said David Williams, a Goddard scientist and data specialist at NSSDC, NASA's permanent archive for space science mission ...

December 2012 Story Tips

2012-12-07

DISASTER RESPONSE – Limiting access . . . Ensuring that only people who have legitimate business are allowed to enter areas hit by floods, hurricanes or other disasters is a big challenge, but Credentialing 2.0 offers a software solution. "Obviously, first responders, utility crews, tree cutters, disaster relief workers and members of the media have reasons to be on the scene, but there's no efficient way to control access," said Oak Ridge National Laboratory's David Resseguie, who leads the Credentialing 2.0 development team. The ORNL system helps officials to control ...

Combining two genome analysis approaches supports immune system contribution to autism

2012-12-07

Researchers using novel approaches and methodologies of identifying genes that contribute to the development of autism have found evidence that disturbances in several immune-system-related pathways contribute to development of autism spectrum disorders. The report published December 4 in the open-access journal PLOS ONE powerfully supports a role for the immune function in autism by integrating analysis of autism-associated DNA sequence variations with that of markers identified in studies of families affected by autism. "Others have talked about immune function contributions ...

Tiny structure gives big boost to solar power

2012-12-07

Princeton researchers have found a simple and economic way to nearly triple the efficiency of organic solar cells, the cheap and flexible plastic devices that many scientists believe could be the future of solar power. The researchers, led by electrical engineer Stephen Chou, were able to increase the efficiency 175 percent by using a nanostructured "sandwich" of metal and plastic that collects and traps light. Chou said the technology also should increase the efficiency of conventional inorganic solar collectors, such as standard silicon solar panels, although he cautioned ...

Valuable tool for predicting pain genes in people

2012-12-07

Scientists in Australia and Austria have described a "network map" of genes involved in pain perception, with remarkable similarity from fruit flies to people. The work should help identify new analgesic drugs. Dr Greg Neely from the Garvan institute of Medical Research in Sydney and Professor Josef Penninger from the Austrian Academy of Sciences in Vienna had previously screened the 14,000 genes in the fly genome and identified 580 genes identified with heat perception. In the current study, using a database from the US National Centre for Biotechnology Information, ...

Severe acute kidney injuries rise rapidly nationwide

2012-12-07

Severe acute kidney injuries are becoming more common in the United States, rising 10 percent per year and doubling over the last decade, according to a retrospective study at the University of California, San Francisco (UCSF). The study, to be published online this week in the Journal of the American Society of Nephrology, analyzed information from a national database that monitors all causes of hospitalizations and used this data to estimate the total number of acute kidney injuries in the United States that were severe enough to require a patient to be placed on dialysis. ...

Fasting may benefit patients with epilepsy, Johns Hopkins Children's Center study suggests

2012-12-07

Children with persistent and drug-resistant seizures treated with the high-fat, low-carbohydrate ketogenic diet may get an added therapeutic benefit from periodic fasting, according to a small Johns Hopkins Children's Center study. The results, published online Dec. 3 in the journal Epilepsy Research, suggest the ketogenic diet and fasting can work in tandem to reduce seizures but appear do so through different mechanisms -- a finding that challenges the longstanding assumption that the two share a common mechanism. "Our findings suggest that fasting does not merely ...

Paradox of aging: The older we get, the better we feel?

2012-12-07

Presently, there are about 40 million Americans over the age of 65, with the fastest-growing segment of the population over 80 years old. Traditionally, aging has been viewed as a period of progressive decline in physical, cognitive and psychosocial functioning, and aging is viewed by many as the "number one public health problem" facing Americans today. But this negative view of aging contrasts with results of a comprehensive study of 1,006 older adults in San Diego by researchers from the University of California, San Diego School of Medicine and Stanford University. ...

New IDSA guidelines aim to reduce death, disability, and cost of prosthetic joint infections

2012-12-07

[EMBARGOED FOR DEC. 7, 2012, ARLINGTON, Va.] – Of the one million people each year who get hips and knees replaced, as many as 20,000 will get an infection in the new joint, a number that is expected to skyrocket in the next 20 years. Multispecialty physician teams need to work together to reduce disability, death and costs associated with the ever-growing number of these prosthetic joint infections, note the first guidelines on the topic being released by the Infectious Diseases Society of America (IDSA). "There are very few things that improve quality of life as much ...

TGen-US Oncology data guides treatment of metastatic triple-negative breast cancer patients

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: